X4 Pharmaceuticals Plunges 13.99% on Price Target Cut

On August 14, 2025, X4 Pharmaceuticals experienced a significant drop of 13.99% in pre-market trading, reflecting a notable shift in investor sentiment towards the company.

H.C. Wainwright has revised its price target for X4 Pharmaceuticals (NASDAQ:XFOR) to $3.50 from $7.00, while maintaining a Buy rating on the stock. This adjustment comes as the firm continues to monitor the company's performance and market conditions.

Despite the lowered price target, H.C. Wainwright has maintained its "Buy" rating, indicating that the firm still sees potential in the company's long-term prospects. This decision suggests that while there may be short-term challenges, the firm believes in the company's ability to overcome them and deliver value to investors.